Aché is involved in the pharmaceutical industry, focusing on providing therapeutic solutions and innovative products to improve health and wellbeing.

Aché

Ferring Pharmaceuticals focuses on developing innovative treatments in reproductive medicine and maternal health, as well as in gastroenterology and urology.

Ferring Pharmaceuticals

UCB Ireland is a Christian media ministry focused on sharing the message of Jesus Christ to the nation of Ireland, particularly in Co. Dublin.

UCB Ireland

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Metric
Company Name	Aché	Ferring Pharmaceuticals	UCB Ireland	Novo Nordisk A/S
Symbol				NVO
MSH ID	BR:COM:ACHE	COM:FERRING	IE:UCBIRELAND	COM:NOVONORDISK
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Consumer Services	Healthcare
Industry	Pharmaceuticals	Pharmaceuticals	Religious Media and Broadcasting	Biotechnology
Country	BR	CH	IE	DK
Stage				Post-IPO Equity
Employee Count				66.02K
Website	ache.com.br	ferring.com	ucbireland.ie	novonordisk.com
LinkedIn				novo-nordisk
Founders

Metric
Market Cap		628.74B
Enterprise Value
Monthly Web Traffic	400.93K	900.07K
Web Traffic Growth	-0.12	0.05
Valuation
Raised Capital		22M

Metric
Revenue				32.89B
Revenue (LTM)
Revenue (NTM)
Gross Profit				27.83B
EBITDA				15.99B
Operating Income				14.53B
Net Income				11.85B
EPS				2.64
Diluted EPS				2.64
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.85
Operating Profit Margin				0.45
EBITDA Margin				0.49
Net Profit Margin				0.37
Return on Equity				0.92
Return on Assets				0.30
Return on Capital Employed				0.82

BR:COM:ACHE

Aché

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				43.81
P/B Ratio				34.40
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				18.71
EV Multiple				36.90

Metric
Days Sales Outstanding				118.27
Days Payables Outstanding				261.32
Days Inventory Outstanding				332.44
Operating Cycle				442.92
Cash Conversion Cycle				294.76
Asset Turnover				0.82

Metric
Operating Cash Flow				15.42B
Free Cash Flow				9.91B
Cash Flow to Debt				4.03
Operating Cash Flow/Sales				0.47
Free Cash Flow Yield				0.02

Metric
Cash & Equivalents				2.04B
Accounts Receivable				-2.01B
Inventory				4.50B
Goodwill				632.18M
Debt to Capitalization				0.34
Debt to Assets				0.09
Current Ratio				0.82
Quick Ratio				0.75

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				0.07
R&D to Revenue				0.14
SG&A to Revenue				0.02